The recent FDA decision will reverberate across the industry and the healthcare sector for many reasons.

Conventional wisdom says that insiders and 10% owners really only buy shares of a company for one reason — they believe the stock price will rise and they want to profit from it. Insider buying can be an encouraging signal for potential investors.

Biotech stocks extended their weekly gains for the fourth straight week, thanks to broader market buoyancy, positive FDA decisions and vaccine news.

When looking for the best growth stocks, it makes sense to focus on consistent growth leaders with a proven ability to outperform over time.

Many investors tend to avoid buying stocks that are rising strongly. A healthy dose of patience and skepticism is a sensible approach in the market.